Firivumab
- Product NameFirivumab
- CAS1443004-15-6
- CBNumberCB48080916
- MW0
- MOL FileMol file
- MSDS FileSDS
Firivumab Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| ChemScene CS-0628712 | 1mg | $325 | Firivumab 95.00% |
Buy |
| ChemScene CS-0628712 | 5mg | $812 | Firivumab 95.00% |
Buy |
| ChemScene CS-0628712 | 10mg | $1300 | Firivumab 95.00% |
Buy |
| aablocks AA02AP0S | 1mg | $369 | Firivumab >98% |
Buy |
| aablocks AA02AP0S | 5mg | $869 | Firivumab >98% |
Buy |
Firivumab Chemical Properties,Usage,Production
Uses
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice[1][2][3].in vivo
Firivumab (CT-P22; CT120; 7.5-30 mg/kg; IP; Twenty-four hours post-infection) shows 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group[1].
CT-P27 (adding 7.5 mg/kg Firivumab and 7.5 mg/kg CT149) shows full protection in A/California/04/09 (H1N1)-treated mice[1].
| Animal Model: | Six- to nine-week-old female BALB/c mice with A/California/04/09 (H1N1) and A/Philippines/2/1982 (H3N2)[1] |
| Dosage: | 7.5, 15, 30 mg/kg |
| Administration: | IP; Twenty-four hours post-infection |
| Result: | Showed 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group. Could not protect mice from H3N2 infection. |
References
[1] Kye Sook Yi, et al. Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. PLoS One. 2020 Jul 29;15(7):e0236172. DOI:10.1371/journal.pone.0236172[2] John H Beigel, et al. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):a038463. DOI:10.1101/cshperspect.a038463
[3] Seung Suh Hong, et al. Composition comprising at least two influenza a virus-neutralizing-binding molecules. EP3011968A1.
Preparation Products And Raw materials
Firivumab Suppliers
Global(17)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 177-54423994 17754423994 |
2853530910@QQ.com | China | 7996 | 62 | |
| 15817493340 | 981810490@qq.com | China | 1577 | 58 | |
| 027-65317797 15926423062 |
422450190@qq.com | China | 10302 | 58 | |
| 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 | |
| 027-65279366 18108604356 |
products@biolabreagent.com | China | 9864 | 58 | |
| 13720134139 086-15871494362 13720134139 |
orders@jknbiochem.com | China | 7284 | 58 | |
| 021-65675885 18964387627 |
customer_service@efebio.com | China | 11963 | 58 | |
| 027-027-16602739303 16602739303 |
673003916@qq.com | China | 4622 | 58 | |
| 15111215862 18229892877 |
3062105966@qq.com | China | 5571 | 58 | |
| 0573-83568680 18057391398 |
3956524501@qq.com | China | 1441 | 58 |
1443004-15-6, FirivumabRelated Search
PROMPT×
PROMPT
The WhatsApp is temporarily not supported in mainland China
The WhatsApp is temporarily not supported in mainland China
Cancel
Determine